13 Best Pharma Stocks to Buy According to Wall Street Analysts

1. Immunovant, Inc. (NASDAQ:IMVT)

Analyst Upside: 165.33%

Number of Hedge Fund Holders: 37

Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 26, Sam Slutsky, an analyst from LifeSci Capital, maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the associated price target at $50. He based the rating on the notable market opportunity for the company’s IMVT-1402 for the treatment of Graves’ disease, which is a leading cause of hyperthyroidism and has considerable unmet medical need.

The disease impacts around a million patients in the US, and current treatments typically render a majority of patients uncontrolled or intolerant. Since alternative therapies for the disease also have considerable drawbacks, the analyst reasoned that IMVT-1402 has potential as a novel, disease-modifying therapy. It reduces pathogenic IgG autoantibodies to target the disease’s root cause, and positive proof-of-concept data from a first-generation anti-FcRn supports the therapy’s efficacy.

The analyst further reasoned that feedback from key opinion leaders highlights the significant need and demand for such targeted treatments, painting a positive picture for Immunovant, Inc. (NASDAQ:IMVT). Apart from IMVT-1402’s dual effects in Graves’ disease and thyroid eye disease, the company’s ongoing trials further support the optimistic rating.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

While we acknowledge the potential of IMVT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMVT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.